BILLERICA, Mass. --(BUSINESS WIRE)--May 12, 2026-- Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that Vandana Sriram, its Chief Financial Officer (“CFO”) will depart the Company.

Reports $36.4 million in revenue and approximately $103 million of cash and marketable securities Company prioritizing product roadmap and investing in initiatives to drive commercial effectiveness BILLERICA, Mass. --(BUSINESS WIRE)--May 6, 2026-- Quanterix Corporation   (NASDAQ: QTRX), a company

Agreement supports the identification of patients eligible for Alzheimer’s disease biomarker testing through Tempus Next and enables neurologists to order LucentAD® Complete on Tempus’ clinical ordering platform BILLERICA, Mass. --(BUSINESS WIRE)--May 6, 2026-- Lucent Diagnostics, a brand of

BILLERICA, Mass. --(BUSINESS WIRE)--Apr. 24, 2026-- Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that it will host a conference call on Wednesday, May 6, 2026, at 4:30 p.m.

Novel Assay, Developed on Akoya PhenoImager HT Platform with Opal Chemistry, Becomes First to Predict Both Locoregional Recurrence Risk and Radiation Therapy Benefit in Early-Stage Invasive Breast Cancer LAGUNA HILLS, Calif. & BILLERICA, Mass. --(BUSINESS WIRE)--Apr.

The Content Innovation Engine brings together Akoya's spatial biology platform and Quanterix's immunoassay infrastructure to systematically unlock cancer biology and accelerate the path toward clinical application BILLERICA, Mass. --(BUSINESS WIRE)--Apr.

BILLERICA, Mass. --(BUSINESS WIRE)--Mar. 27, 2026-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection (the “Company”), today announced that the Company’s 2026 annual meeting of shareholders (the “Annual Meeting”) will be held

Reports $43.9 million in revenue and cash balance of $122 million Company expects to achieve cash flow breakeven during 2026 BILLERICA, Mass. --(BUSINESS WIRE)--Mar. 2, 2026-- Quanterix Corporation   (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection,

Collaboration Aims to Expand Access to Early Detection of Potential Disease Marker BILLERICA, Mass. --(BUSINESS WIRE)--Mar. 2, 2026-- Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced a partnership with Life Line Screening (LLS), a national organization focused on

BILLERICA, Mass. --(BUSINESS WIRE)--Feb. 26, 2026-- Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its executive leadership team will participate in the following investor